IN THE NEWS
Johnson & Johnson Vision’s new presbyopia-correcting IOL, Tecnis Odyssey, is designed to provide full visual range, reduced night vision symptoms and best-in-category contrast and low-light performance. Tecnis Odyssey is expected to be fully commercially available in the United States during the second half of 2024.
RxSight Inc. announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power designed to slightly extend the depth of focus. The RxSight Light Adjustable Lens system is the first commercially available IOL technology that can be adjusted after surgery.
Viatris Inc. announced the US commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (eg, phenylephrine) or parasympatholytic (eg, tropicamide) agents in the United States.
Iveric Bio, An Astellas Company, announced the CMS has assigned a unique, permanent HCPS J-code for IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy secondary to AMD. The new J-code, J2782, became effective April 1, 2024.
Glaukos Corp. announced the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma (OAG). The new J-code for iDose TR, J7355, will become effective July 1, 2024.
OASIS Medical launched the SOFT PLUG Extended Duration 180-T Tapered Plug. The plugs are designed with a .25-mm tapered end for ease of insertion into the punctal opening. The plug then gradually widens to a 0.6-mm diameter at the top end to contribute to occlusion of the canaliculus. After insertion through the punctal opening and into the canaliculus it degrades in approximately 180 days.
Orbis International and FundamentalVR launched a virtual reality (VR) training solution built to support students and residents learning to perform surgery to treat cataracts. The tool integrates VR, haptic feedback, cloud assessment data and off-the-shelf hardware to create a solution for cataract surgical training in resource-limited settings.
Nicox SA released the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470, a novel nitric oxide-donating bimatoprost eyedrop, to latanoprost in the lowering of IOP in patients with OAG or ocular hypertension. Trial data showed the NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or ocular hypertension at all six time points.
GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT Phase 3 clinical trial with LUMEVOQ (GS010; lenadogene nolparvovec). The results showed a sustained efficacy 4 years after injection, along with a continued benefit at 4 years in bilaterally treated patients: clinically meaningful improvement of at least 15 letters relative to their observed nadir.
LENZ Therapeutics announced positive results from its Phase 3 CLARITY study of two formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In Phase 3 (CLARITY 1 and 2), LNZ100 (1.75% aceclidine) achieved the primary and key secondary endpoints, with three-lines or greater improvement in BCDVA at near, without losing one-line or more in distance visual acuity. CLARITY 2 Day 1 results showed 71% achieved three-lines or greater improvement at 30 minutes.
Sight Sciences presented data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System at ASCRS. Clinical results demonstrate at 36-months, the long-term efficacy of the OMNI Surgical System for primary OAG. Also, TearCare data demonstrated tear break-up, meibomian gland, and dry eye symptom improvement.
NovaBay Pharmaceuticals and Eyenovia Inc. signed a co-promotion agreement to commercialize prescription ophthalmic products to physicians across the United States. NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05%, and Eyenovia will market NovaBay’s prescription Avenova Antimicrobial Lid & Lash Solution through its Mydcombi and Clobetasol sales representatives.
